Jing Li

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.

T. Heise, J. DeVries, A. Mari, 2022, The lancet. Diabetes & endocrinology.

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

T. Heise, J. DeVries, Z. Milicevic, 2023, Diabetes care.

714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism

T. Heise, A. Mari, Z. Milicevic, 2022, Diabetes.